(Q52608144)

4 May 2018

title

Phase 1 study of the novel vascular disrupting agent plinabulin (NPI-2358) and docetaxel. (English)

1 reference

4 May 2018

author name string

Michael Millward

1

1 reference

4 May 2018

Paul Mainwaring

2

1 reference

4 May 2018

Alain Mita

3

1 reference

4 May 2018

Kristine Federico

4

1 reference

4 May 2018

G K Lloyd

5

1 reference

4 May 2018

Natasha Reddinger

6

1 reference

4 May 2018

Steffan Nawrocki

7

1 reference

4 May 2018

Monica Mita

8

1 reference

4 May 2018

Matthew A Spear

9

1 reference

4 May 2018

publication date

16 February 2011

1 reference

4 May 2018

Investigational New Drugs

published in

1 reference

4 May 2018

volume

30

1 reference

4 May 2018

issue

3

1 reference

4 May 2018

page(s)

1065-1073

1 reference

4 May 2018

https://scigraph.springernature.com/pub.10.1007/s10637-011-9642-4

exact match

0 references

cites work

Endothelial cell proliferation as a novel approach to targeting tumour therapy

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9642-4

Relationship of vascular maturation in breast cancer blood vessels to vascular density and metastasis, assessed by expression of a novel basement membrane component, LH39.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9642-4

Sorafenib in advanced clear-cell renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9642-4

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9642-4

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9642-4

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9642-4

Phase II trial of bevacizumab in combination with weekly docetaxel in metastatic breast cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9642-4

Sorafenib: a review of its use in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9642-4

Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9642-4

Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9642-4

Phase I clinical evaluation of weekly administration of the novel vascular-targeting agent, ZD6126, in patients with solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9642-4

The Proportion of Patients with Metastatic Non-small Cell Lung Cancer Potentially Eligible for Treatment with Bevacizumab: A Single Institutional Survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9642-4

Survival without toxicity for cisplatin plus pemetrexed versus cisplatin plus gemcitabine in chemonaïve patients with advanced non-small cell lung cancer: a risk-benefit analysis of a large phase III study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9642-4

NPI-2358 is a tubulin-depolymerizing agent: in-vitro evidence for activity as a tumor vascular-disrupting agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9642-4

Phase 1 first-in-human trial of the vascular disrupting agent plinabulin(NPI-2358) in patients with solid tumors or lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9642-4

Phase I and pharmacokinetic study of lapatinib and docetaxel in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9642-4

Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9642-4

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9642-4

Targeting the tumor vasculature: enhancing antitumor efficacy through combination treatment with ZD6126 and ZD6474.

21 January 2018

1 reference

12 December 2020

The Current Status of Targeting Tumour Vasculature as a Means of Cancer Therapy: An Overview

1 reference

12 December 2020

The proportion of patients with metastatic non-small cell lung cancer potentially eligible for treatment with bevacizumab: a single institutional survey.

1 reference

12 December 2020

Dual targeting of tumor vasculature: combining Avastin and vascular disrupting agents (CA4P or OXi4503).

1 reference

12 December 2020

10.1007/S10637-011-9642-4

Identifiers

DOI

1 reference

4 May 2018

PubMed ID

21327495

1 reference

4 May 2018